Teva Announces Launch of a Generic Version of EXJADE® (deferasirox) Tablets For Oral Suspension in the United States
JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of EXJADE®1 (deferasirox)
Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors
BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced the nominations of Shawn Cline
Sobi to sell another rare disease drug in Saudi Arabia
The Saudi Food & Drug Authority (SFDA) has approved Swedish Orphan Biovitrum’s (Sobi) Elocta (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life, for the treatment of haemophilia A.
Sobi’s hereditary tyrosinemia drug approved in Saudi Arabia
The Saudi Food and Drug Administration (SFDA) has approved Swedish Orphan Biovitrum’s (Sobi) Orfadin (nitisinone) capsules in all strengths (2 mg, 5 mg, 10 mg and 20 mg) for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
Tiziana testing drug for fifth most common cancer
Tiziana Life Sciences a cancer drugs making focused clinical stage biotechnology company got approval in Israel to start testing inhibitor of cell cycle dependent kinases (CDKs), milciclib in a phase II clinical trial.
Novartis in-licenses dry eye therapeutic ECF843 worldwide
Novartis said Thursday it has exercised an option to in-license ECF843 for ophthalmic indications worldwide excepot of Europe, without revealing financial and other terms of this transaction.
Cannabics Pharmaceuticals gets final report of its research on antitumor properties of cannabinoids in Israel
Cannabics Pharmaceuticals has received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer.
Xbrane Biopharma to deliver its cancer drug to Middle East
Xbrane Biopharma, a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long acting injectables, has delivered its first batch of Spherotide to its partner in the Middle East to a value of €0.7 million.
Adding blueberries to the diet may be an overall positive diet
New research published in the European Journal of Nutrition found that daily consumption of the equivalent of one cup of fresh blueberries, given as 24 g of freeze-dried powder, showed …
90% of the cases analysed are carriers of at least one genetic mutation
Conceiving and bearing a child is a blessing in a couple’s life. While they are lost in rejoicing the good news, they often ignore the fact that they can be passing some serious genetic disorders to their child. Along with the features and traits, a child also inherits genetic disorders which their parents are the carrier.